Philip Hemme, Author at Labiotech.eu

About

Young French-German Entrepreneur, Co-founder & CEO of Labiotech.eu. High-level table tennis player, and German beer/French Wine lover 🙂

Articles by Philip Hemme

News and Trends 21 Mar 2016

This CEO was responsible for the Only German Biotech IPO in 2015…

Whilst at the Sachs conference last week, I had the chance to meet with Oliver Schacht, the CEO of Curetis. It’s the only German Biotech which went public last year and this was a good enough reason to have a chat (the company is also really interesting, obviously). Curetis is based in Stuttgart in the […]

March 21, 2016 - 1 minutemin - By Philip Hemme

News and Trends 18 Mar 2016

ITW: GapSummit, the Event for the European Bio-leaders of Tomorrow

Where can you meet the next generation of European Biotech leaders in one single event? For sure at GapSummit 2016, which will be held next April 4th to 6th in Cambridge, UK. We had a chat with the young Director and President of the event, Lisa Altmann-Richer, to have more details. Could you first present Global Biotech […]

March 18, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 17 Mar 2016

“We have Reshaped how Innovation occurs inside Pierre Fabre”

This is what Laurent Audoly, Head of R&D of Pierre Fabre, told me at the SACHS conference in Zurich last Tuesday. The French Big Pharma recently opened its fund for innovation and it was a great opportunity to get a better insight into it. Pierre Fabre is the 3rd largest Pharma in France, counting over […]

March 17, 2016 - 1 minutemin - By Philip Hemme

mission therapeutics sachs interview zurich labiotech biotech

News and Trends 16 Mar 2016

Interviewing the Biotech which raised the Biggest European Round in 2016 so far

Yesterday I flew to Switzerland for the day, to gage what was going on at the 9th Annual Sachs conference for European Biotech CEOs. Here I had the chance to Interview Cambridge UK’s Mission Therapeutics on investment and technology.. Panel discussions covered Partnering and Investment for various therapeutic platforms – in MedTech, Diagnostics and generally ‘Israel’ (and […]

March 16, 2016 - 1 minutemin - By Philip Hemme

News and Trends 14 Mar 2016

DBV: “These Additional Results Confirm our Potential of solving the Peanut Allergy problem Worldwide”

DBV Technologies (Paris) was just under the spotlight in Los Angeles at the biggest allergy convention worldwide (2016 AAAAI Annual Meeting). Their Viaskin skin patch could potentially eradicate peanut allergies for patients altogether… Last year, it was the first French Biotech to be listed on the NASDAQ (raising €90M), it then raised €255M (!) in a follow-up round […]

March 14, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 12 Mar 2016

What happened this week? 5 Berlin Biotechs, Cancer Infographic, EMA Fast Track

Monday: Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them Tuesday: 5 Biotech Companies you Should know in Berlin Wednesday: EMA Launches its own Fast Track for Breakthrough Therapies Thursday: The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed Friday: Interview: Can this Natural Acid replace Petroleum for the […]

March 12, 2016 - 1 minutemin - By Philip Hemme

News and Trends 1 Mar 2016

Here’s why this leading EU Investor turned to NASH

Akarna Therapeutics (US & UK) just raised $15M (€13M) in a series B round led by Forbion Partners – one of the leading VCs from Europe. Also run by existing New York investors New Science Ventures and Third Point, the round purpose was to raise funding to develop a new drug for the liver disease Non-alcoholic steatohepatitis (NASH). I […]

March 1, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 27 Feb 2016

What happened this week? European Biotechs on NASDAQ, Onxeo’s CEO Interview, NGS Battle

Monday: Meet the CEO of a Confident Orphan Oncology Biotech from France & Denmark Tuesday: 7 Trendy European Biotechs Listed on the NASDAQ in 2016 Wednesday: Your Microbiome even Impacts how Tall you are! Thursday: NGS Battle: Illumina is now suing Oxford Nanopore (and it looks suspicious) Friday: Faces of Bioart: Depicting the Psychology of Petri […]

February 27, 2016 - 1 minutemin - By Philip Hemme

biotech nasdaq stock top biopharma finance 2016

News and Trends 23 Feb 2016

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock exchange in the world, based in New York, and the largest for high-tech companies. It seems to be the real test for a European biotech to […]

February 23, 2016 - 6 minutesmins - By Philip Hemme

onxeo cancer beleodaq interview Judith Greciet

News and Trends 22 Feb 2016

Meet the CEO of a Confident Orphan Oncology Biotech from France & Denmark

Last week, I was in Paris to meet with one of our Investors, during which time I also had a chance to visit the French Cancer Biotech, Onxeo. I met with the CEO of Onxeo, Judith Greciet, who was confident about the future of the company. She moved into the role in 2011 after having spent […]

February 22, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 19 Feb 2016

Biotech of the week: NZYTech, one of the biggest Portuguese Biotech companies

This week, we leave the cold of Norway and head South-West to warmer climates. Not Spain this time, we arrive in the capital of Portugal, Lisbon. This city has a nightlife that can rival Madrid, Castles looking onto beaches and is the location of our biotech of the week, NZYTech. City: Lisbon, Portugal Founded: 2008 Employees: 50 […]

February 19, 2016 - 1 minutemin - By Philip Hemme

News and Trends 16 Feb 2016

The Only Real European Biotech Unicorns in 2016

Unicorns are private fast-growing companies valued more than a billion euro/dollars. This club is getting bigger and bigger, 146 companies while I’m writing this article (look at the full list on the Wall Street Journal). There is a very reduced number of Biotech unicorns worldwide and even less in Europe. There are actually only 3: […]

February 16, 2016 - 3 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Philip Hemme

About

Articles by Philip Hemme

This CEO was responsible for the Only German Biotech IPO in 2015…

ITW: GapSummit, the Event for the European Bio-leaders of Tomorrow

“We have Reshaped how Innovation occurs inside Pierre Fabre”

Interviewing the Biotech which raised the Biggest European Round in 2016 so far

DBV: “These Additional Results Confirm our Potential of solving the Peanut Allergy problem Worldwide”

What happened this week? 5 Berlin Biotechs, Cancer Infographic, EMA Fast Track

Here’s why this leading EU Investor turned to NASH

What happened this week? European Biotechs on NASDAQ, Onxeo’s CEO Interview, NGS Battle

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Meet the CEO of a Confident Orphan Oncology Biotech from France & Denmark

Biotech of the week: NZYTech, one of the biggest Portuguese Biotech companies

The Only Real European Biotech Unicorns in 2016

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Philip Hemme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!